Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025
1/6 16:50
ALLO-316 shows promising response rates in advanced renal cell carcinoma, utilizing Dagger technology for enhanced CAR T cell efficacy....